{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:09:59Z","timestamp":1791518999719,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Science & Technology Department of Sichuan Province","award":["2018SZ0166"],"award-info":[{"award-number":["2018SZ0166"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jns.2020.116772","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T03:06:16Z","timestamp":1583895976000},"page":"116772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The tolerability and safety profile of eslicarbazepine acetate in neurological disorders"],"prefix":"10.1016","volume":"413","author":[{"given":"Li-na","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-jiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2020.116772_bb0005","author":"European Medicines Agency"},{"key":"10.1016\/j.jns.2020.116772_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2014.09.008","article-title":"Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide","author":"Hebeisen","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jns.2020.116772_bb0015","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awu339","article-title":"Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug","author":"Doeser","year":"2015","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.jns.2020.116772_bb0020","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1212\/WNL.0000000000002497","article-title":"Conversion to eslicarbazepine acetate monotherapy A pooled analysis of 2 phase III studies","volume":"86","author":"Sperling","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.116772_bb0025","article-title":"Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder i","author":"Grunze","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jns.2020.116772_bb0030","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2011"},{"key":"10.1016\/j.jns.2020.116772_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","author":"Bucher","year":"1997","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jns.2020.116772_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","author":"Higgins","year":"2003","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jns.2020.116772_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials","author":"Zaccara","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2020.116772_bb0050","article-title":"The adverse event profile of levetiracetam: A meta-analysis on children and adults","author":"Prezioso","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.jns.2020.116772_bb0055","author":"Bial - Portela C S.A"},{"key":"10.1016\/j.jns.2020.116772_bb0060","author":"Bial - Portela C S.A"},{"key":"10.1016\/j.jns.2020.116772_bb0065","author":"Bial - Portela C S.A"},{"key":"10.1016\/j.jns.2020.116772_bb0070","author":"Bial - Portela C S.A"},{"key":"10.1016\/j.jns.2020.116772_bb0075","author":"Bial - Portela C S.A"},{"key":"10.1016\/j.jns.2020.116772_bb0080","author":"Bial - Portela C S.A"},{"key":"10.1016\/j.jns.2020.116772_bb0085","author":"Bial - Portela C S.A"},{"key":"10.1016\/j.jns.2020.116772_bb0090","author":"Bial - Portela C S.A"},{"key":"10.1016\/j.jns.2020.116772_bb0095","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2020.116772_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2020.116772_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2020.116772_bb0110","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2020.116772_bb0115","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":"Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures","author":"Elger","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2020.116772_bb0120","doi-asserted-by":"crossref","DOI":"10.1111\/cns.12765","article-title":"Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: data from four double-blind placebo-controlled pivotal phase III clinical studies","author":"Elger","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jns.2020.116772_bb0125","doi-asserted-by":"crossref","DOI":"10.2147\/CE.S142858","article-title":"Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: An evidence-based review of efficacy, safety and place in therapy","author":"Lattanzi","year":"2018","journal-title":"Core Evid."},{"key":"10.1016\/j.jns.2020.116772_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2018.03.023","article-title":"Antiepileptic drugs-induced hyponatremia: Review and analysis of 560 hospitalized patients","author":"Intravooth","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2020.116772_bb0135","doi-asserted-by":"crossref","DOI":"10.1006\/ebeh.2000.0126","article-title":"Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use","author":"Schmidt","year":"2000","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jns.2020.116772_bb0140","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1G209","article-title":"Carbamazepine-induced hyponatremia: assessment of risk factors","author":"Kuz","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jns.2020.116772_bb0145","doi-asserted-by":"crossref","DOI":"10.1080\/17512433.2018.1421066","article-title":"Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence","author":"Willems","year":"2018","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2020.116772_bb0150","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2017.1248399","article-title":"Hyponatremia induced by antiepileptic drugs in patients with epilepsy","author":"Lu","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jns.2020.116772_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2020.116772_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.03.018","article-title":"Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures","author":"Chung","year":"2019","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2020.116772_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011412.pub3","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jns.2020.116772_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.seizure.2017.02.019","article-title":"Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01","author":"Kay","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.jns.2020.116772_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.nurt.2006.10.002","article-title":"Lacosamide","author":"Doty","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jns.2020.116772_bb0180","doi-asserted-by":"crossref","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":"Lacosamide: a review of preclinical properties","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.jns.2020.116772_bb0185","doi-asserted-by":"crossref","DOI":"10.1517\/14656566.2010.488639","article-title":"Lacosamide: new adjunctive treatment option for partial-onset seizures","author":"Chung","year":"2010","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jns.2020.116772_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","author":"Biton","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jns.2020.116772_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2016.08.006","article-title":"A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy","author":"Brigo","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2020.116772_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2017.11.008","article-title":"Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy","author":"Li-na","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2020.116772_bb0205","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2012.03589.x","article-title":"The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials","author":"Zaccara","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2020.116772_bb0210","doi-asserted-by":"crossref","DOI":"10.1177\/0091270010391789","article-title":"Evaluation of eslicarbazepine acetate on cardiac repolarization in a thorough QT\/QTc study","author":"Vaz-Da-Silva","year":"2012","journal-title":"J. Clin. Pharmacol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20301088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20301088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:51:02Z","timestamp":1758383462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20301088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":42,"alternative-id":["S0022510X20301088"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.116772","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The tolerability and safety profile of eslicarbazepine acetate in neurological disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.116772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116772"}}